skip to content
Primary navigation

LAMA/LABA Combination

DrugInhaled LAMA/LABA Combination (Long-Acting Antimuscarinic Antagonist/Long-Acting Beta2 Agonist)

October 2017

Therapeutic area - COPD


  • Stiolto Respimat (tiotropium/olodaterol) [Boehringer Ingelheim]


  • Anoro Ellipta (umeclidinium/vilanterol) [GSK]
  • Bevespi Aerosphere (glycopyrrolate/formoterol) [AstraZeneca]
  • Utibron Neohaler (glycopyrrolate/indacaterol) [Sunovion]

Approval criteria for nonpreferred products

  • Patient must be 18 years of age or older AND
  • Patient has a diagnosis of COPD AND
  • Patient has tried and failed the preferred product

Quantity limits

1 inhaler per 30-day supply


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top